Binding of human papillomavirus 16 E6 to p53 and E6AP is impaired by monoclonal antibodies directed against the second zinc-binding domain of E6.

Date publication

avril 2005

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DERYCKERE Francois , Dr MASSON Murielle , Pr ORFANOUDAKIS Georges , Dr TRAVE Gilles , Pr WEISS Etienne

Tous les auteurs :
Lagrange M, Charbonnier S, Orfanoudakis G, Robinson P, Zanier K, Masson M, Lutz Y, Trave G, Weiss E, Deryckere F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/15784893

Résumé

The E6 protein of cancer-associated human papillomavirus type 16 (16E6) binds to p53 and, in association with E6AP, promotes its degradation through the ubiquitin-proteasome pathway. The aim of this work was to develop monoclonal antibodies against 16E6 and to test their effect on the binding of 16E6 to p53 and E6AP, and on the degradation of p53. It was shown that an antibody directed against the N terminus of 16E6 inhibited E6AP-dependent binding to p53 and degradation of p53, whereas two different antibodies directed to the second zinc-binding domain of 16E6 reduced 16E6 E6AP-independent binding to p53 and binding to E6AP but not degradation of p53.

Référence

J Gen Virol. 2005 Apr;86(Pt 4):1001-7.